Fakultät für Chemie - Former
Uni von A-Z
Bielefeld University > Department of Chemistry > Organic Chemistry III > Team > Former

Personal data for Dr. Christine Weiß

  Dr. Christine Weiß
Dr. Christine Weiß
PhD student
Raum: F2-264
Telefon: 0521 106 2147

Curriculum Vitae

seit 12/2008 PhD student in the group of Prof. Norbert Sewald at the University Bielefeld, Germany. Dissertation title “Synthese von Cryptophycin-Analoga für SAR- und subzelluläre Lokalisationsstudien”
04/2008‑10/2008 Diploma thesis in organic chemistry in the group of Prof. Dr. Frank Glorius at the Westfälische Wilhelms-Universität (WWU), Münster, Germany. Titel: “Ionenpaarkatalyse und asymmetrische Hydrierung-Entwicklung neuer Methoden”
2003‑2008 Studies in chemistry at the Westfälischen Wilhelms-Universität Münster, Germany
06/2002 Allgemeine Hochschulreife (Abitur), Gymnasium “St. Ursula” Dorsten, Germany


10/2011 “Insights for PhD Students”, BASF SE, Ludwigshafen, Germany
06/2011 61st Meeting of Nobel Laureates, Lindau, Germany
04‑10/2007 Research internship in the group of Prof. G. C. Bazan at the University of California Santa Barbara (UCSB), California
04/2007 Stipend for a subject-based internship abroad, DAAD, German Academic Exchange Service

Total Synthesis of Cryptophycin-Fluorophor-Conjugates

Cryptophycins are a family of 16-membered cyclic depsipeptides produced as secondary metabolites by cyanobacteria. The retrosynthetic analysis of cryptophycin-1 leads to the four units A-D. Cryptophycin-1 and some artificial analogues proved to be extremely cytotoxic and cytostatic in biological screening studies. The bioactivity of cryptophycins is based on their ability to interact with tubulin. They display considerable cytotoxicity both against multidrug-resistant tumour cell lines and solid tumours. Cryptophycin-1 and cryptophycin-52 display an antitumour activity with 100 to 1000-fold increased potency compared to the chemotherapeutics paclitaxel and vinblastine. As a consequence, cryptophycin derivatives are considered as potential antitumour drugs. Cryptophycin-52 entered phase II clinical trials but failed due to its high neurotoxicity.
Modified cryptophycins were synthesised for structure-activity relationship studies and biochemical application. Fluorescent labelling of the cryptophycin moiety should allow qualitative and quantitative determinations of cellular events at molecular level.


Diethyl Tartrate (Review), C. Weiss, Synlett2011, 1333-1334.

Synthesis and Application of a Chiral Diborate, Y. Loewer, C. Weiss, A. T. Biju, R. Fröhlich, F. Glorius, J. Org. Chem.2011, 76, 2324-2327.

Approaches for the Synthesis of Functionalized Cryptophycins, B. Sammet, T. Bogner, M. Nahrwold, C. Weiss, N. Sewald, J. Org. Chem.2010, 75, 6953-6960.

Poster Presentations

03/2011 “Localization of a Cryptophycin Prodrug inside Cells”, 10th German Peptide Symposium, Berlin, Germany
09/2010 “Total Synthesis of Azide Functionalized Cryptophycins”, 31st European Peptide Symposium, Copenhagen, Denmark
03/2010 “Total Synthesis of Azide Functionalized Cryptophycins”, Frontiers in Medicinal Chemistry, Münster, Germany
07/2009 “Total Synthesis of Modified Cryptophycins”, 21st International Symposium: Synthesis in Organic Chemistry, Oxford, UK

Oral Presentations

09/2011 “Modified Cryptophycins – Synthesis of Novel Chemotherapeutics”, GDCh Wissenschaftsforum Chemie, Bremen, Germany